CalciMedica, Inc. (CALC) · Oct 16, 2026 · Exec change
CFO departure — Resignation effective after the September 30, 2026 10-Q; no successor disclosed
CalciMedica’s CFO is leaving after the September-quarter filing, adding leadership uncertainty as the biotech advances Auxora and CM5480.
CalciMedica is a clinical-stage biotech advancing intravenous Auxora for hospital-based inflammatory and cardiopulmonary diseases, alongside oral CM5480 for chronic treatment. Its near-term story is execution: advancing the pulmonary-hypertension program while working toward future regulatory and clinical milestones.
The immediate change is a CFO transition, not a pipeline update. Stephen Bardin resigned to pursue another opportunity, with the departure taking effect only after the company files its quarterly report for the quarter ended September 30, 2026. 〔0〕
The timing limits the immediate reporting disruption but leaves an open execution question. Bardin remains in place through the upcoming 10-Q, but the filing names no replacement or interim CFO. That matters more for a cash-burning clinical-stage company preparing multiple development milestones than it would for a mature operating business, because finance leadership supports cash planning, financing execution, and public-company reporting. The filing says the resignation was not due to disagreement with CalciMedica. 〔1〕
Relative to expectations, this is a modest negative surprise rather than a change to the drug-development thesis. The filing does not alter Auxora’s programs, CM5480, regulatory plans, or clinical timelines; it adds management-transition risk while the company is trying to execute on those plans. The absence of a named successor keeps the practical impact unresolved.
Bottom line: This is a small but real setback to execution and governance, not a fundamental pipeline event. The next meaningful signal is whether CalciMedica appoints a capable finance replacement without disrupting its upcoming reporting and development plans.
Q3 10-Q filing and CFO transition
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!